Targeted delivery of CCL3 reprograms macrophage antigen presentation and enhances the efficacy of immune checkpoint blockade therapy in hepatocellular carcinoma
This study highlights the pivotal role of CCL3 in reshaping the TIME and enhancing antitumor immunity in HCC. By promoting immune cell recruitment and enhancing antigen presentation, CCL3 demonstrates significant potential to improve the efficacy of immunotherapy, particularly in combination with immune checkpoint inhibitors. Targeting CCL3 may help to overcome the immunosuppressive TIME in HCC and improve patient outcomes.
Authors
- Cejun Yang (ORCID: https://orcid.org/0000-0003-4205-3736)
- Wei Wang (ORCID: https://orcid.org/0000-0002-3409-7846)
- Di Wu (ORCID: https://orcid.org/0000-0002-8109-5368)
- Muqi Liu (ORCID: https://orcid.org/0009-0007-7631-2798)
- Lu Cao (ORCID: https://orcid.org/0000-0002-3602-0340)
- Linzhe Li (ORCID: https://orcid.org/0000-0002-4941-3127)
- Yao Deng (ORCID: https://orcid.org/0000-0002-7429-3147)
- Wei Li (ORCID: https://orcid.org/0000-0002-7267-6494)
- Xiaoqian Ma (ORCID: https://orcid.org/0000-0002-8315-9927)
- Pengfei Rong (ORCID: https://orcid.org/0000-0001-5473-1982)
- Juan Zhang (ORCID: https://orcid.org/0000-0003-4673-3448)
- Min Yang (ORCID: https://orcid.org/0000-0002-2319-8086)
- Huaping Liu (ORCID: https://orcid.org/0000-0001-7017-4127)
- Qi Liang
- Xingshi Gu
- Yanan Li (ORCID: https://orcid.org/0000-0001-5999-0430)
Institutions
- Central South University (CN)
- Centro de Cirugía de Mínima Invasión Jesús Usón (ES)
- Third Xiangya Hospital (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1136/jitc-2024-010947
- Citations
- 8
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 6.38
Funders
- National Natural Science Foundation of China
- Science and Technology Program of Hunan Province